1-year and 4-year change in total hip BMD (g/cm2) by selected diabetes medication use, combined sexes analyses for all participants and stratified by sex
| Response variable . | All participants . | Men . | Women . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Medication use: mean (SD) [n] . | Medication nonuse: mean (SD) [n] . | P valuea . | Medication use: mean (SD) [n] . | Medication nonuse: mean (SD) [n] . | P valuea . | Medication use: mean (SD) [n] . | Medication nonuse: mean (SD) [n] . | P valuea . | |
| Thiazolidinedione | |||||||||
| 1-year ΔBMD | −0.014 (0.036) [n = 233] | −0.008 (0.029) [n = 983] | 0.02 | −0.012 (0.036) [n = 115] | −0.007 (0.026) [n = 356] | 0.15 | −0.015 (0.035) [n = 118] | −0.008 (0.031) [n = 627] | 0.07 |
| 4-year ΔBMD | −0.034 (0.051) [n = 216] | −0.033 (0.048) [n = 886] | 0.81 | −0.012 (0.036) [n = 102] | −0.007 (0.026) [n = 309] | 0.23 | −0.039 (0.053) [n = 114] | −0.039 (0.051) [n = 577] | 0.99 |
| Sulfonylurea | |||||||||
| 1-year ΔBMD | −0.009 (0.031) [n = 584] | −0.009 (0.031) [n = 632] | 0.96 | −0.009 (0.027) [n = 248] | −0.008 (0.031) [n = 223] | 0.68 | −0.009 (0.033) [n = 336] | 0.010 (0.030) [n409] | 0.75 |
| 4-year ΔBMD | −0.038 (0.048) [n = 519] | −0.030 (0.048) [n = 583] | 0.00 | −0.028 (0.040) [n = 210] | −0.020 (0.042) [n = 201] | 0.04 | −0.045 (0.052) [n = 309] | −0.035 (0.050) [n = 382] | 0.01 |
| Insulin (any form) | |||||||||
| 1-year ΔBMD | −0.012 (0.033) [n = 202] | −0.009 (0.030) [n = 1016] | 0.22 | −0.009 (0.036) [n = 82] | −0.008 (0.027) [n = 389] | 0.90 | −0.014 (0.031) [n = 120] | −0.009 (0.032) [n = 627] | 0.12 |
| 4-year ΔBMD | −0.033 (0.051) [n = 188] | −0.034 (0.048) [n = 916] | 0.83 | −0.023 (0.052) [n = 72] | −0.024 (0.039) [n = 339] | 0.85 | −0.039 (0.050) [n = 116] | −0.040 (0.052) [n = 577] | 0.95 |
| Response variable . | All participants . | Men . | Women . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Medication use: mean (SD) [n] . | Medication nonuse: mean (SD) [n] . | P valuea . | Medication use: mean (SD) [n] . | Medication nonuse: mean (SD) [n] . | P valuea . | Medication use: mean (SD) [n] . | Medication nonuse: mean (SD) [n] . | P valuea . | |
| Thiazolidinedione | |||||||||
| 1-year ΔBMD | −0.014 (0.036) [n = 233] | −0.008 (0.029) [n = 983] | 0.02 | −0.012 (0.036) [n = 115] | −0.007 (0.026) [n = 356] | 0.15 | −0.015 (0.035) [n = 118] | −0.008 (0.031) [n = 627] | 0.07 |
| 4-year ΔBMD | −0.034 (0.051) [n = 216] | −0.033 (0.048) [n = 886] | 0.81 | −0.012 (0.036) [n = 102] | −0.007 (0.026) [n = 309] | 0.23 | −0.039 (0.053) [n = 114] | −0.039 (0.051) [n = 577] | 0.99 |
| Sulfonylurea | |||||||||
| 1-year ΔBMD | −0.009 (0.031) [n = 584] | −0.009 (0.031) [n = 632] | 0.96 | −0.009 (0.027) [n = 248] | −0.008 (0.031) [n = 223] | 0.68 | −0.009 (0.033) [n = 336] | 0.010 (0.030) [n409] | 0.75 |
| 4-year ΔBMD | −0.038 (0.048) [n = 519] | −0.030 (0.048) [n = 583] | 0.00 | −0.028 (0.040) [n = 210] | −0.020 (0.042) [n = 201] | 0.04 | −0.045 (0.052) [n = 309] | −0.035 (0.050) [n = 382] | 0.01 |
| Insulin (any form) | |||||||||
| 1-year ΔBMD | −0.012 (0.033) [n = 202] | −0.009 (0.030) [n = 1016] | 0.22 | −0.009 (0.036) [n = 82] | −0.008 (0.027) [n = 389] | 0.90 | −0.014 (0.031) [n = 120] | −0.009 (0.032) [n = 627] | 0.12 |
| 4-year ΔBMD | −0.033 (0.051) [n = 188] | −0.034 (0.048) [n = 916] | 0.83 | −0.023 (0.052) [n = 72] | −0.024 (0.039) [n = 339] | 0.85 | −0.039 (0.050) [n = 116] | −0.040 (0.052) [n = 577] | 0.95 |
P values in bold are statistically significant at an alpha = 0.05 level.
Abbreviation: ΔBMD, change in bone mineral density.
aP values were derived from a 2-sided t test.
1-year and 4-year change in total hip BMD (g/cm2) by selected diabetes medication use, combined sexes analyses for all participants and stratified by sex
| Response variable . | All participants . | Men . | Women . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Medication use: mean (SD) [n] . | Medication nonuse: mean (SD) [n] . | P valuea . | Medication use: mean (SD) [n] . | Medication nonuse: mean (SD) [n] . | P valuea . | Medication use: mean (SD) [n] . | Medication nonuse: mean (SD) [n] . | P valuea . | |
| Thiazolidinedione | |||||||||
| 1-year ΔBMD | −0.014 (0.036) [n = 233] | −0.008 (0.029) [n = 983] | 0.02 | −0.012 (0.036) [n = 115] | −0.007 (0.026) [n = 356] | 0.15 | −0.015 (0.035) [n = 118] | −0.008 (0.031) [n = 627] | 0.07 |
| 4-year ΔBMD | −0.034 (0.051) [n = 216] | −0.033 (0.048) [n = 886] | 0.81 | −0.012 (0.036) [n = 102] | −0.007 (0.026) [n = 309] | 0.23 | −0.039 (0.053) [n = 114] | −0.039 (0.051) [n = 577] | 0.99 |
| Sulfonylurea | |||||||||
| 1-year ΔBMD | −0.009 (0.031) [n = 584] | −0.009 (0.031) [n = 632] | 0.96 | −0.009 (0.027) [n = 248] | −0.008 (0.031) [n = 223] | 0.68 | −0.009 (0.033) [n = 336] | 0.010 (0.030) [n409] | 0.75 |
| 4-year ΔBMD | −0.038 (0.048) [n = 519] | −0.030 (0.048) [n = 583] | 0.00 | −0.028 (0.040) [n = 210] | −0.020 (0.042) [n = 201] | 0.04 | −0.045 (0.052) [n = 309] | −0.035 (0.050) [n = 382] | 0.01 |
| Insulin (any form) | |||||||||
| 1-year ΔBMD | −0.012 (0.033) [n = 202] | −0.009 (0.030) [n = 1016] | 0.22 | −0.009 (0.036) [n = 82] | −0.008 (0.027) [n = 389] | 0.90 | −0.014 (0.031) [n = 120] | −0.009 (0.032) [n = 627] | 0.12 |
| 4-year ΔBMD | −0.033 (0.051) [n = 188] | −0.034 (0.048) [n = 916] | 0.83 | −0.023 (0.052) [n = 72] | −0.024 (0.039) [n = 339] | 0.85 | −0.039 (0.050) [n = 116] | −0.040 (0.052) [n = 577] | 0.95 |
| Response variable . | All participants . | Men . | Women . | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Medication use: mean (SD) [n] . | Medication nonuse: mean (SD) [n] . | P valuea . | Medication use: mean (SD) [n] . | Medication nonuse: mean (SD) [n] . | P valuea . | Medication use: mean (SD) [n] . | Medication nonuse: mean (SD) [n] . | P valuea . | |
| Thiazolidinedione | |||||||||
| 1-year ΔBMD | −0.014 (0.036) [n = 233] | −0.008 (0.029) [n = 983] | 0.02 | −0.012 (0.036) [n = 115] | −0.007 (0.026) [n = 356] | 0.15 | −0.015 (0.035) [n = 118] | −0.008 (0.031) [n = 627] | 0.07 |
| 4-year ΔBMD | −0.034 (0.051) [n = 216] | −0.033 (0.048) [n = 886] | 0.81 | −0.012 (0.036) [n = 102] | −0.007 (0.026) [n = 309] | 0.23 | −0.039 (0.053) [n = 114] | −0.039 (0.051) [n = 577] | 0.99 |
| Sulfonylurea | |||||||||
| 1-year ΔBMD | −0.009 (0.031) [n = 584] | −0.009 (0.031) [n = 632] | 0.96 | −0.009 (0.027) [n = 248] | −0.008 (0.031) [n = 223] | 0.68 | −0.009 (0.033) [n = 336] | 0.010 (0.030) [n409] | 0.75 |
| 4-year ΔBMD | −0.038 (0.048) [n = 519] | −0.030 (0.048) [n = 583] | 0.00 | −0.028 (0.040) [n = 210] | −0.020 (0.042) [n = 201] | 0.04 | −0.045 (0.052) [n = 309] | −0.035 (0.050) [n = 382] | 0.01 |
| Insulin (any form) | |||||||||
| 1-year ΔBMD | −0.012 (0.033) [n = 202] | −0.009 (0.030) [n = 1016] | 0.22 | −0.009 (0.036) [n = 82] | −0.008 (0.027) [n = 389] | 0.90 | −0.014 (0.031) [n = 120] | −0.009 (0.032) [n = 627] | 0.12 |
| 4-year ΔBMD | −0.033 (0.051) [n = 188] | −0.034 (0.048) [n = 916] | 0.83 | −0.023 (0.052) [n = 72] | −0.024 (0.039) [n = 339] | 0.85 | −0.039 (0.050) [n = 116] | −0.040 (0.052) [n = 577] | 0.95 |
P values in bold are statistically significant at an alpha = 0.05 level.
Abbreviation: ΔBMD, change in bone mineral density.
aP values were derived from a 2-sided t test.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
